We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Transarterial Chemotherapy with Zinostatin Stimalamer for Hepatocellular Carcinoma.
- Authors
Okusaka, Takuji; Okada, Shuichi; Ishii, Hiroshi; Ikeda, Masafumi; Nakasuka, Hidekazu; Nagahama, Hiroyasu; Iwata, Ryoko; Furukawa, Hiroyoshi; Takayasu, Kenichi; Nakanishi, Yukihiro; Sakamoto, Michiie; Hirohashi, Setsuo; Yoshimori, Masayoshi
- Abstract
Zinostatin stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC). Thirty HCC patients underwent transcatheter arterial injection of 4 mg SMANCS-lipiodol emulsion. Their responses were evaluated by computed tomography 1 month after treatment. Complete response (CR) was defined as disappearance or 100% necrosis of all tumors. Partial response (PR) was defined as ≧50% reduction and/or ≧50% necrosis. We regarded the lipiodol accumulation in tumors as being necrotic. CR and PR were observed in 8 patients (27%) and 4 patients (13%), respectively, and the overall response rate (CR + PR/all patients) was 40% (12/30). Of 12 patients whose serum α-fetoprotein levels had been more than 200 ng/ml before treatment, 5 patients (42%) showed more than 50% reduction in this level within 1 month after treatment. Toxicity was quite acceptable, although grade 4 toxicity (WHO) was observed as liver dysfunction in 1 patient. Transarterial chemotherapy with SMANCS, which is well tolerated, appears to have moderate antitumor effect in patients with HCC.
- Subjects
CANCER chemotherapy; DRUG therapy; LIVER cancer; CANCER treatment; ANTINEOPLASTIC agents
- Publication
Oncology, 1998, Vol 55, Issue 4, p276
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000011863